Navigation Links
MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
Date:5/16/2008

MOUNTAIN VIEW, Calif., May 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008, at 9:00 am (ET) in New York City.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The Company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
2. Transdel Pharmaceuticals Closes $4 Million Financing
3. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
5. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
7. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
8. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
9. Medimetriks Pharmaceuticals, Inc. Begins Operations
10. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
11. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented ... expansion clinical trial for its lead drug candidate, AC0010, at the World Conference ... was to determine the safety, antitumor activity, and recommended phase II dosage of ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new study published in ... previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute ... of blood sampling may improve the value of a blood-based test.” The study ...
(Date:12/7/2016)... NE (PRWEB) , ... December 07, 2016 , ... ... systems integration, today announced that it has become a Wonderware Certified System Integrator ... System Integrator Partner by Schneider Electric Software. , “The System Integrator Partner certification ...
(Date:12/7/2016)... 2016 Neogen Corporation (NASDAQ: NEOG ... Kephart as its chief science officer — a ... responsibilities at Neogen effective Jan. 1. Kephart ... agribusiness unit of Thermo Fisher Scientific, as well as ... His extensive industry experience also includes the management of ...
Breaking Biology Technology:
(Date:12/7/2016)... , December 7, 2016 According to a new market ... Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region ... to grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by ... Continue Reading ... MarketsandMarkets ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported ... to over 40 granted and pending patents. ... , The Company,s IP portfolio ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... hardware components needed to estimate the force and pressure applied to touch ...
(Date:12/7/2016)... Dec. 7, 2016   Avanade is helping ... One teams in history, exploit biometric data in order ... and maintain the competitive edge against their rivals after ... Avanade has worked with Williams during the ... biometric data (heart rate, breathing rate, temperature and peak ...
Breaking Biology News(10 mins):